Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.67 +0.77%

+$0.03 today

Market cap
$100.28M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

MOLN Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Molecular Partners AGNASDAQ: MOLN

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was CHF 0, compared with CHF 0 a year earlier. Trailing-twelve-month revenue was CHF 0.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near CHF 0 or moves back toward the trailing-twelve-month quarterly average of CHF 0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 0— QoQ
Last fiscal yearDec 2025
CHF 0-100.0% YoY
LTMMar 2026
CHF 0-100.0% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

CHF · from the income statement

Latest · FY2025
0 CHF
Year-over-year change
-100.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How MOLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -100.0% is the lowest of 4, against a peer median of -10.7%.
MOLN Competitors
Revenue for MOLN and competitors
Company Period LTM YoY 3-year CAGR
ALECAlector, Inc.LTM Mar 2026$18.42M USD-79.2%-46.0%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$3.17M USD+164.1%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$1.78M USD—-32.4%
CRDFCardiff Oncology, Inc.LTM Mar 2026$525K USD-10.7%+15.4%
MOLNMolecular Partners AGLTM Mar 2026CHF 0 CHF-100.0%—
PEPGPepGen Inc.LTM Mar 2026$0 USD——
NKTXNkarta, Inc.LTM Mar 2026$0 USD——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD——
ELTXElicio Therapeutics, Inc.LTM Mar 2026$0 USD——
Peer median (excluding MOLN) —-10.7%-32.4%

Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.33M189.56M7.04M4.97M0
Cost of Revenue55.72M50.75M47.84M47.5M2.58M
Gross Profit(46.39M)138.81M(40.81M)(42.53M)(2.58M)
Gross Margin-497.2%73.2%-579.8%-855.8%—
Research & Development55.72M50.75M48.78M48.6M40.19M
Selling, General & Admin16.91M21.82M19M17.16M14.87M
Operating Expenses72.75M72.94M20.3M18.68M50.89M
Depreciation & Amortization2.57M2.39M2.42M2.37M2.14M
EBITDA(60.66M)119M(59.52M)(51.65M)(59.49M)
EBITDA Margin-650.2%62.8%-845.6%-1039.2%—
Operating Income(63.42M)116.61M(61.11M)(61.22M)(58.12M)
Operating Margin-679.7%61.5%-868.3%-1231.7%—
Interest Income108.28K1.2M4.28M3.38M1.52M
Interest Expense608.14K648.12K49K25K18K
Other Income / Expenses(365K)1.24M(876K)7.18M(3.53M)
Income Before Tax(63.78M)117.85M(61.98M)(54.04M)(61.65M)
Pre-Tax Margin-683.6%62.2%-880.7%-1087.3%—
Income Tax Expense2K002K2K
Net Income(63.79M)117.85M(61.98M)(54.04M)(61.65M)
Net Margin-683.7%62.2%-880.7%-1087.4%—
EPS (Basic)(2.06)3.63(1.89)(1.59)(1.65)
EPS (Diluted)(2.06)3.54(1.89)(1.59)(1.65)
Weighted Avg Shares31.01M32.47M32.77M34.03M37.27M
Weighted Avg Shares (Diluted)31.01M33.27M32.77M34.03M37.27M

Molecular Partners AG

NASDAQ:MOLN

Intrinsic Alpha fair value

Locked

Current Price

$2.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.